Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Table 2 Response to EGFR-TKIs in 453 NSCLC patients with different EGFR genotypes

Variate	Exon 19 deletion (n = 270)	Exon 21 L858R mutation (n = 183)	P value^a
Best response (cases)			0.074
CR	4	2
PR	145	78
SD	105	84
PD	16	19
MDT (months)
CR/PR	13.0	14.6	0.874
SD	13.7	11.9	0.193
ORR (%)
Total	55.2	43.7	0.017
Line 1	60.0	49.5	0.108
Line ≥ 2	49.6	32.4	0.018
Gefitinib	59.2	43.2	0.005
Erlotinib	55.8	39.1	0.184
Icotinib	33.3	58.8	0.089
DCR (%)
Total	94.1	89.6	0.081
Line 1	96.2	92.4	0.208
Line ≥2	91.7	84.5	0.113

CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, ORR = CR + PR, DCR disease control rate, DCR = CR + PR + SD, MDT median duration of treatment, ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor
^aAnalyzed by using χ² test

ISSN: 2523-3548